Beta-amyloid aggregation inhibitors for the treatment of Alzheimer's disease: dream or reality?
Amyloid (Abeta) deposition remains a hallmark in the pathology of Alzheimer's disease (AD). Important drug discovery efforts dedicated to the inhibition of the polymerization process leading to amyloid neurotoxicity are pursued by academic groups and the pharmaceutical industry as a potential preventive treatment for AD. The aim of this review is to up-date current knowledge on the amyloid aggregation process and the various available peptidic and non-peptidic Abeta aggregation inhibitors.